Katherine R Calvo

Suggest Changes
Learn More
PURPOSE To evaluate clinical activity and target modulation of vandetanib in women with recurrent ovarian cancer. EXPERIMENTAL DESIGN A phase II trial of orally administered vandetanib 300 mg daily(More)